Using Analytics to Maximize Copay Program Effectiveness

Click here to view the session

As manufacturers began to shift from pure product sampling strategies to more blended ones comprised of sampling, vouchers, and copays, the advantages generated were clearly evident: the entire cost of the product was no longer always being subsidized. As such, manufacturers were content to receive data on the numbers of redemptions, patients, and prescribers participating. However, as the copay industry has matured, these measures have become less and less adequate. Instead, pharmaceutical manufacturers are looking to analytics, with their rich sources of evidence, demonstrations of convincing payback, and sophisticated predictive models as requirements of their patient access suppliers. In this webcast, TrialCard provides an overview of the analytic data that we use to help our manufacturers to design the most effective campaigns and to assess their effectiveness.

Featured Speaker:
Paul LeVine, Vice President of Analytic Services, TrialCard

Sponsored by:

You must be a registered member of MMM to post a comment.

Next Article in Features

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters